(within 6 months) histories of stroke were not eligible for the study, and patients with any history of cerebrovascular disease were declared ineligible early in the study. The small number of patients (89, or 2.3%) with any history of neurological disease, intermittent cerebral ischemic attacks, or stroke who were enrolled before the stricter eligibility criteria were imposed or on the basis of incomplete baseline information experienced an increased frequency of intracerebral hemorrhage compared with patients without such histories (3.4% versus 0.5%). Mortality at 6 weeks after presentation among 23 patients who had intracerebral hemorrhage was 47.8%. Intracerebral hemorrhage is a severe but infrequent complication of rt-PA therapy for acute myocardial infarction. The combined frequency of intracerebral hemorrhage, subdural hematoma, and cerebral infarction after treatment with 100 mg rt-PA is comparable to that observed in other trials with thrombolytic agents in acute myocardial infarction. (Circulation 1991;83:448-459) 
T hrombolytic therapy is widely used in the treatment of acute myocardial infarction (AMI). The evidence that timely thrombolysis significantly decreases short-term'-4 and longterM5,6 mortality is compelling. However, the use of thrombolytic agents, with the desired pharmacological effect of activation of the fibrinolytic system, entails some risk of bleeding.7'8 Thrombolytic agents are not believed to cause obvious spontaneous bleeding from normal blood vessels9 but may unmask underlying or ongoing vascular pathology. Intracranial bleeding, the most serious complication of thrombolysis, has been reported in numerous studies.2,3,8'10-14 However, even without thrombolytic intervention, strokes, both hemorrhagic and ischemic, have been documented as complications of AMI and its treatment with anticoagulants. 3,8"15-'7 The Thrombolysis in Myocardial Infarction (TIMI), Phase IL pilot and clinical trial was designed to assess the effects on morbidity, mortality, and left ventricular function of percutaneous transluminal coronary angioplasty (PTCA) after intravenous recombinant tissue-type plasminogen activator (rt-PA) administration to patients with AMI.18,19 A pilot study testing TIMI II procedures preceded the randomized clinical trial. 20 During the TIMI II pilot and early in the beginning of the TIMI II clinical trial, an unexpected number of intracranial hemorrhages occurred in patients on 150 mg rt-PA10'20; therefore, the dose was reduced to 100 mg rt-PA.'0'21 In this report, we summarize our observations on the incidence and types of adverse neurological events and possible risk factors in the entire 3,924-patient cohort.
Methods

Study Population and Treatment Regimens
The TIMI IL study included 24 principal investigators representing 50 hospitals at university and community medical centers. 19 The principal objective was to determine whether PTCA is a useful adjunct to single-chain rt-PA (alteplase, Activase®, supplied by Genentech Inc., South San Francisco, Calif.) combined with heparin and aspirin in patients with AMI. Two subtrials, TIMI I-A and TIMI LI-B, were incorporated in the main study. TIMI IL-A was designed to evaluate immediate versus delayed invasive strategies,18 and TIMI I-B was designed to evaluate immediate intravenous versus deferred oral ,3-blocker therapy. '9 In the TIMI II pilot, patients were assigned to immediate invasive strategy in TIMI I-A clinical centers or to delayed invasive strategy and immediate intravenous ,-blocker therapy (if eligible) in TIMI II-B main clinical centers; in TIMI I-B satellite hospitals, patients were assigned to immediate intravenous 1-blocker therapy (if eligible) and systematically to either delayed invasive strategy (requiring transport to a main TIMI II clinical center) or conservative strategy. The treatment regimens included rt-PA, heparin, and aspirin for all patients.
Detailed descriptions of the studies and the results have been reported. 18"19 The rt-PA was administered to the first 908 patients in a dose of 150 mg i.v. over 6 hours (90 mg in the first hour, including a 9-mg initial bolus; 20 mg in the second hour; and 10 mg in each of the next 4 hours). The dose was subsequently reduced to 100 mg for the remaining 3,016 patients (60 mg in the first hour, including a 6-mg initial bolus; 20 mg in the second hour; and 5 mg in each of the next 4 hours). An initial 5,000-IU bolus of intravenous heparin was given at the start of rt-PA infusion; continuous infusion began at 1 hour at a rate of 1,000 IU/hr, and the dose was then adjusted to maintain the activated partial thromboplastin time between 1.5-fold and twofold that of control.
When intracranial hemorrhages were first recognized as a complication in TIMI II, eligibility criteria were made more restrictive and the aspirin regimen was revised; approximately 2 months later, the dose of rt-PA was reduced from 150 to 100 mg. At the start of the study, patients with histories of cerebrovascular disease (including stroke) were excluded if the cerebrovascular disease had been active within the 6 months before AMI presentation, a policy more conservative than the National Institutes of Health (NIH) Consensus Conference on Thrombolytic Therapy recommendation of 2 months.22 A protocol revision made patients who had histories of ever having stroke or intermittent cerebral ischemic attacks ineligible. After the protocol change, no patients with histories of stroke were admitted to the study. Also, blood pressure criteria were changed from excluding patients with diastolic blood pressures of more than 120 mm Hg by several measurements to excluding patients with any measurement more than 180 mm Hg systolic or 110 mm Hg diastolic at the time of presentation. Aspirin (80 mg/day) on the same day as thrombolytic therapy was part of the study regimen in the first 627 patients in the TIMI 19 Hemostasis analyses. Blood samples were collected on as many patients as possible at baseline (preinfusion) and 50, 300, and 480 minutes after the start of the rt-PA infusion. Fibrinogen, fibrin(ogen) degradation products, rt-PA antigen levels, and plasminogen levels were determined on specimens submitted to the Coagulation Core Laboratory. Details of the sample collection procedure and the analyses have been presented elsewhere. 23 The fibrinogen assay was based on the coagulation rate,24 the fibrin(ogen) degradation products assay on inhibition by patient's blood serum of agglutination of fibrinogen-coated red blood cells with anti-fibrinogen antiserum,25 the rt-PA antigen level on a monoclonal antibody-based enzyme-linked immunosorbent assay,26 and the plasminogen level on a chromogenic substrate assay after addition of excess streptokinase.27 Activated partial thromboplastin times were determined at the participating centers on separate blood samples by routine, local laboratory procedures.
Statistical analysis. Probability values and confidence intervals for percentages, proportions, and odds ratios were calculated using standard Z tests, Fisher's "exact" tests, and estimates of variance.28 To adjust for multiple testing, a probability value between 0.01 and 0.001 for two-sided tests has been specified as providing some evidence of differences, and probability values of less than 0.001 have been specified as providing strong evidence of differences.
Step-up multiple logistic regression29 was used to adjust for baseline characteristics. Twenty-three baseline characteristics were evaluated. The step-up procedure permitted addition of these variables to the regression analysis until the probability value was more than 0.05. To include age as a continuous variable with a range of values similar to the discrete variables, it was expressed as (age -57)/10. All statistical tests were performed using the BMDP statistical software package, University of California Press, Berkeley, Calif.
Results
A total of 3,924 patients were enrolled in the TIMI II pilot and clinical trial.18-20 Their allocation with respect to dose of rt-PA and treatment strategy is summarized in Table 1 .
Frequency, Timing, and Outcome ofAdverse Neurological Events
The frequency of the different types of adverse neurological events is summarized in Table 2 . Nine patients (1.0%) receiving the combination of 150 mg rt-PA, heparin, and aspirin had cerebral infarctions, 24 hours of the initiation of treatment. Among patients treated with 150 mg rt-PA, one intracerebral hemorrhage occurred after heparin therapy had been discontinued and 17 hours after the start of rt-PA in a patient with severe hypertension that clinical center investigators thought to be well enough controlled at the time of enrollment to permit thrombolytic therapy, but the patient proved to be difficult to maintain normotensive. On the 100 mg rt-PA regimen, an intracerebral hemorrhage on day 2 was diagnosed on the basis of a CT scan, which also showed an arteriovenous malformation in the area of the hemorrhage, and an intracerebral hemorrhage occurred on day 9 after coronary artery bypass graft surgery. The majority (16 of 29) of cerebral infarctions occurred more than 48 hours after the initiation of therapy. There were no differences between the two rt-PA regimens in the timing of cerebral infarctions or intracerebral hemorrhages. Two of the patients with subdural hematomas experienced the onset of neurological symptoms while rt-PA was infusing. The other two subdural hematoma patients developed neurological symptoms within 12 hours of the start of rt-PA infusion.
The differences in prognosis after intracerebral hemorrhage between 150 mg and 100 mg rt-PA regimen patients were not statistically significant; recovery tended to be more favorable among the 100 The results of available hemostasis analyses for patients who developed intracerebral hemorrhage or cerebral infarction are summarized in Table 6 . No important differences were observed in any of the parameters either between patients with intracerebral hemorrhage and patients with cerebral infarction or between these groups and the total cohort of patients with plasma specimens analyzed. In the entire cohort of patients, those treated with 150 mg rt-PA had lower post-treatment levels of fibrinogen and plasminogen and higher levels of fibrin(ogen) degradation products and rt-PA antigen than patients treated with 100 mg rt-PA, regardless of hemorrhage. The proportions of patients with and without intracerebral hemorrhage who had at least one activated partial thromboplastin time of 90 seconds or more on the day of study entry or the following day were not different (61% versus 61%), nor were the proportions of patients with and without cerebral infarction who had at least one activated partial thromboplastin time of 90 seconds or more on the day of study entry or the following day (59% versus 61%). rt-PA Dose and Patient Baseline Characteristics
The frequency of intracerebral hemorrhage and cerebral infarction according to rt-PA dose and baseline characteristics of the patients are summarized in Tables 7 and 8 , respectively. The 150 mg rt-PA dose was associated with an increased frequency of intracerebral hemorrhage compared with the 100 mg rt-PA dose (p<0.01).
Eligibility criteria always excluded patients with recent (within 6 months) stroke and were made more restrictive early in the study to exclude patients with any known history of cerebrovascular disease. Even so, the small number of patients (89) with prior 
Hemorrhagic Conversion of Cerebral Infarction
Cerebral infarctions were followed by hemorrhagic conversion (i.e., bleeding into the infarcted brain) in five patients receiving 100 mg rt-PA and three patients receiving 150 mg rt-PA. Two of the five patients treated with 100 mg rt-PA had hemorrhagic conversions recognized on CT scans reviewed centrally, but no additional neurological deficits were associated with the hemorrhagic conversions. These two cerebral infarctions occurred more than 1 week (8 and 10 days) after thrombolytic therapy. The abnormal areas on their CT scans were neither homogeneously dense nor extensive. One patient treated with 150 mg rt-PA had a hemorrhagic conversion identified in the TIMI clinical center as an intracranial hemorrhage on the same day as administration of thrombolytic therapy. This patient has been counted in previous reports as having had an intracranial hemorrhage.20 Progressing neurological deficits were associated with this hemorrhagic conversion. The abnormal areas on the CT scan were both homogeneously dense and extensive. This pa- adverse neurological events. Of these 33 intracranial hemorrhages, 23 were classified as intracerebral hemorrhages, four as subdural hematomas, and six as cerebral infarctions with hemorrhagic conversion. All intracerebral hemorrhages and subdural hematomas reported in TIMI II have been counted in previous reports as intracranial hemorrhages. Twenty-three cerebral infarctions were reported by the clinical centers in addition to the six with hemorrhagic conversion reported as intracranial hemorrhages. Two of these 23 cerebral infarctions were followed by hemorrhagic conversion but without increasing neurological deficits. A total of eight patients had cerebral infarction followed by hemorrhagic conversion in the TIMI II pilot and clinical trial. The observed excess in frequency of intracerebral hemorrhage among patients with histories of neurological disease, stroke, or intermittent cerebral ischemic attacks is based on events occurring in only three patients. Consequently, the estimate of the increase as sevenfold is not precise (95% confidence interval about the odds ratio, 1.94-22.81). Broad confidence intervals apply to all of the increases in frequency of intracerebral hemorrhage associated with baseline characteristics. Nonetheless, it seems important to consider both the severity and the magnitude of risk of intracerebral hemorrhage when choosing therapy.
The initial TIMI II exclusion criteria made patients with severe hypertension at the time of presentation ineligible. The stricter criteria imposed in the protocol changes made when intracranial hemorrhages were first recognized in TIMI II made patients with moderate but uncontrolled hypertension ineligible.
The decision to exclude patients with any history of cerebrovascular disease and patients with high systolic or diastolic blood pressures at presentation was based on a small number of observations in patients receiving 150 mg rt-PA. The estimates of the frequency of intracranial hemorrhage among these patients were far from precise. One additional or one less patient with intracranial hemorrhage would have changed by one half the proportion of patients presenting with intracranial hemorrhage among those with systolic blood pressure of more than 180 mm Hg or diastolic blood pressure of more than 110 mm Hg up to the time of the protocol change. Nonetheless, it seemed prudent for the TIMI investigators to withhold thrombolytic therapy from those with histories of cerebrovascular disease and those with high blood pressure at presentation.
Although one patient's intracerebral hemorrhage was part of a severe hypertensive episode, there was no statistically significant association of a history of hypertension or of high blood pressure with the occurrence of intracerebral hemorrhage in the entire patient population. The timing of most hemorrhages during or within 24 hours of rt-PA administration and the location of the hemorrhages in predominantly lobar locations (with none in the putamen) are further evidence against hypertension as the cause of the other intracerebral hemorrhages seen in TIMI 11.30, 31 The stricter entry criteria may have prevented hypertension-associated intracerebral hemorrhages from occurring in TIMI II patients.
A dose of 150 mg rt-PA combined with aspirin and heparin was associated with a higher frequency of adverse neurological events than that observed after protocol changes to a dose of 100 mg rt-PA combined with aspirin and heparin and somewhat stricter entry criteria. The difference in occurrence of adverse neurological events with 150-and 100-mg regimens could primarily be attributed to an excess of intracerebral hemorrhages in the high-dose group (1.3% versus 0.4%, p<0.01). The In the TIMI II pilot and clinical trial, patient selection and guidelines for concomitant therapy were directed to maintain a balance between rethrombosis in the coronary artery and bleeding at other sites. The occurrence of an activated partial thromboplastin time of 90 seconds or more was not associated with an increased frequency of intracerebral hemorrhage. Because all patients in TIMI II received heparin and t-PA, the distinct effects of heparin, of rt-PA, and of their interaction on the frequency of intracerebral hemorrhage or cerebral infarction cannot be discerned.
Increasing age was associated with an increased frequency of intracerebral hemorrhage. The association of calcium channel blockers with intracerebral hemorrhage has not been reported by others and was not the result of any one agent's effect. All of the patients treated with calcium channel blockers had both hypertension and symptomatic atherosclerosis. Their underlying diseases represent a portion of the spectrum of vascular disease pathogenesis that may have both put them at risk for intracerebral hemorrhage and made them likely candidates for treatment with calcium channel blockers. We do not know why these patients were selected for treatment with calcium channel blockers. Alternatively, calcium channel blockers have cerebral vascular dilatory effects and perhaps antiplatelet effects.34, 35 The association between calcium channel blockers and intracerebral hemorrhage could have been due to chance, to the patients' underlying cerebrovascular disease, or to an effect of calcium channel blockers. Further research will be necessary to distinguish these possibilities.
The associations found with cerebral infarction were for well-established risk factors-age, anterior myocardial infarction, and nonwhite race. among rt-PA-treated patients compared with streptokinase-treated patients (1.3% versus 0.9%).39A40 No differences in the frequency of hemorrhagic stroke comparing rt-PA-treated patients with streptokinasetreated patients were found (0.4% versus 0.3%). The frequency of stroke among rt-PA-treated patients in the GISSI and non-GISSI centers combined was similar to that observed in TIMI II, as was the association of age with stroke. The total adverse neurological event rate among patients treated with 100 mg rt-PA in the TIMI II pilot and clinical trial comprised 0.4% intracerebral hemorrhage (95% confidence interval, 0.1-0.6%), 0.7% cerebral infarction (95% confidence interval, 0.4-1.0%), and 0.1% subdural hematoma. The total rate is not different from the observed event rates in either the control or the rt-PA therapy groups of the major studies of thrombolytic therapy in AMI (Table  9 ). In the TIMI II pilot and clinical trial, patients with intracerebral hemorrhage had unfavorable prognoses. Perhaps, as the Second International Study of Infarct Survival (ISIS-2)2 and GISS141 investigators have suggested, thrombolytic and anticoagulant therapies are responsible for adverse neurological events early in the course of AMI but also improve the prognosis of AMI so that other neurological complications due to severe myocardial infarction and its therapy are reduced in frequency.
